ClinicalTrials.gg

Program

cevolisiran

A development code. Also written as “ALXN2030”.

Its studies are led by AstraZeneca.

Furthest: phase 2, since Dec 13, 20242 company-led studies, 2 open or runningNext primary completion: Oct 11, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca22 open or runningphase 2since Dec 13, 2024Aug 12, 2022Oct 11, 2027phase 2 · NCT06744647
  • Named in AstraZeneca’s own pipeline as cevolisiran (ALXN2030), phase 2, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2022First study: phase 1 study in HealthyFirst studyNCT05501717 · 48 enrolled · United Kingdom
  2. Dec 13, 2024Phase 2 study in Antibody-Mediated RejectionNCT06744647 · 47 enrolled · United States, Brazil, Canada and more

Ahead

  1. Oct 11, 2027Primary completion: phase 2 study in Antibody-Mediated RejectionNCT06744647

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06744647Antibody-Mediated Rejection · United States, Brazil, Canada and more2Active, not recruitingOct 11, 202747
NCT05501717Healthy · United Kingdom1Active, not recruitingOct 9, 202548

How it is read

Names in the registry

  • “ALXN2030”, 2 entries

Codes read as this program: ALXN2030.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.